The Carlat Reports present updates on clinical psychiatry on a weekly basis. What were the most listened to episodes of 2022? We'll start the countdown at #10.
Texas state legislators recently passed a bill that will greatly reduce the prior authorization workload. Will this open the door to the rest of the country?
Does the limited research support that oxcarbazepine is a safer and more effective treatment for bipolar disorder than its FDA-approved cousin, carbamazepine? Here is an overview of the pros and cons from a previous article in The Carlat Psychiatry Report.Pros:Similar effectiveness as other mood stabilizers. In mania and mixed states,...
Which antipsychotics should we consider selecting as the first-line and second-line treatments, and what should we base this decision on? Dr. Aziz addresses this in a past article from The Carlat Psychiatry Report. Here’s some of his advice:Process: Tolerability instead of efficacy should be considered when selecting a first-line treatment.
Ketamine and esketamine have been shown to provide rapid relief of suicidality, however, many lingering doubts have been raised about these medicines. In a previous article from The Carlat Psychiatry Report, Nolan Williams, M.D., discusses the potential negative consequences of ketamine/esketamine treatment. Here are some of Dr. Williams’s tips:It might...
Many mental health apps can be problematic because "most of the apps that are available are poorly designed and lack research support.” Dr. Torous discusses these apps in an article from The Carlat Psychiatry Report. Here is some of his advice.
Today’s episode is one we’ve been sitting with for a long time. We’re talking about how to survive psychologically in a world where hatred is persistent, not abstract,...